课题基金 / 基金详情

REGULATION OF sGC IN sGC/Hsp90/NOS COMPLEXES

REGULATION OF sGC IN sGC/Hsp90/NOS COMPLEXES
sGC/Hsp90/NOS 复合体中 sGC 的调节
批准号:
7024541
负责人:
John D Catravas
金额:
$31.42万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-04-17 至 2008-03-31

项目摘要

项目成果

John D Catravas的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The soluble isoform of guanylate cyclase (sGC) is a heterodimer protein abundant in most tissues and the principal "nitric oxide (NO) receptor", responsible for the synthesis of cGMP in response to activation by NO. Because of the labile nature of NO, the amount of biologically active NO and consequently, the degree of the NO-sGC interaction are inversely related to both the intermolecular distance between sGC and the NO synthase (NOS)-generated NO, as well as the presence of competing ligands, especially superoxide. The NO-superoxide-generated peroxynitrite is a highly reactive, toxic radical responsible for the nitration and deactivation of numerous proteins. Protein-protein interactions are important determinants of NOS activity; in particular, the association of NOS with the ubiquitous heat shock protein 90 (Hsp90) greatly enhances its activity. To date, it has been assumed that sGC exists free in the cytoplasm where it competes with other NO ligands. Contrary to this assumption, we recently discovered that sGC exists in a multi-protein complex involving at least Hsp90 and NOS (eNOS or iNOS), in both endothelial and smooth muscle cells, and that this association enhances its activity in response to either endogenous NO or nitrovasodilator-derived NO, both in vitro and in vivo. This newly discovered Hsp90-sGC complexes provide novel models for understanding the multicellular effects of NO. In the proposed studies, we will investigate the molecular mechanisms of these interactions and test the hypothesis that these new models represent physiological mechanisms aimed at improving sGC activation, maximizing the NO-sGC interaction and at reducing NO scavenging by superoxide.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.vph.2008.06.008
发表时间: 2008-10
期刊: VASCULAR PHARMACOLOGY
影响因子: 4
作者: [Chatterjee, Anuran, Catravas, John D.]
通讯作者: Catravas, John D.
Antidotes against HCI-induced chronic lung injury
  • 批准号:
    10015581
  • 项目类别:
  • 资助金额:
    $45.88万
  • 财政年份:
    2020
  • 负责人:
    John D Catravas
  • 依托单位:
Antidotes against HCI-induced chronic lung injury
  • 批准号:
    10241958
  • 项目类别:
  • 资助金额:
    $45.28万
  • 财政年份:
    2020
  • 负责人:
    John D Catravas
  • 依托单位:
Antidotes against HCI-induced chronic lung injury
  • 批准号:
    10471329
  • 项目类别:
  • 资助金额:
    $44.0万
  • 财政年份:
    2020
  • 负责人:
    John D Catravas
  • 依托单位:
Antidotes against mustard-induced chronic lung injury
  • 批准号:
    9789315
  • 项目类别:
  • 资助金额:
    $19.38万
  • 财政年份:
    2018
  • 负责人:
    John D Catravas
  • 依托单位:
国内基金
海外基金
核桃肽基于Caveolins调控细胞内吞跨血脑屏障的转运机制
  • 批准号:
    22378368
  • 项目类别:
    面上项目
  • 资助金额:
    50万元
  • 批准年份:
    2023
  • 负责人:
    闵伟红
  • 依托单位:
Caveolins在胆囊胆固醇结石形成中的作用
  • 批准号:
    81070366
  • 项目类别:
    面上项目
  • 资助金额:
    32.0万元
  • 批准年份:
    2010
  • 负责人:
    许国强
  • 依托单位:
Caveolae/Caveolins调节血管平滑肌细胞CGRP受体跨膜信号转导作用及开关机制
  • 批准号:
    30572192
  • 项目类别:
    面上项目
  • 资助金额:
    8.0万元
  • 批准年份:
    2005
  • 负责人:
    秦旭平
  • 依托单位: